Kanker Payudara

A Challenging Tenure Begins: Erica Schwartz Takes the Helm at a Bifurcated CDC

• Chemotherapy and Targeted Therapy

A Challenging Tenure Begins: Erica Schwartz Takes the Helm at a Bifurcated CDC

Reynand Wu August 6, 2026

By BioPharma Investigative Desk August 6, 2026 In a move that marks a pivotal, if precarious, turning...

Read More Read more about A Challenging Tenure Begins: Erica Schwartz Takes the Helm at a Bifurcated CDC

The Erosion of Global Health Diplomacy: An Analysis of the Post-USAID Landscape

• Breast Cancer Legislation and Policy

The Erosion of Global Health Diplomacy: An Analysis of the Post-USAID Landscape

Reynand Wu August 6, 2026

Editorial Note: Originally published in May 2025, this comprehensive report has been updated to reflect the evolving...

Read More Read more about The Erosion of Global Health Diplomacy: An Analysis of the Post-USAID Landscape

The Quiet Revolution: Reclaiming Well-Being Through the Art of Deep Relaxation

• Integrative Oncology and Holistic Care

The Quiet Revolution: Reclaiming Well-Being Through the Art of Deep Relaxation

Rifan Muazin August 6, 2026

Published: August 6, 2026 Editor’s Note: This feature is part of our archival series, revisiting foundational insights...

Read More Read more about The Quiet Revolution: Reclaiming Well-Being Through the Art of Deep Relaxation

A New Era for Breast Cancer Screening: Pioneering Personalized Risk Assessment

• Medical Research and Clinical Trials

A New Era for Breast Cancer Screening: Pioneering Personalized Risk Assessment

Laily UPN August 6, 2026

San Antonio, TX – December 12, 2023 – A landmark study, poised to fundamentally redefine breast cancer...

Read More Read more about A New Era for Breast Cancer Screening: Pioneering Personalized Risk Assessment

Ending the "Wait-and-See" Era: AbbVie’s Maviret Redefines Hepatitis C Treatment

• Treatment Innovations

Ending the "Wait-and-See" Era: AbbVie’s Maviret Redefines Hepatitis C Treatment

Iffa Jayyana August 6, 2026

In a landmark shift for global public health, AbbVie’s direct-acting antiviral (DAA) therapy, Maviret (glecaprevir/pibrentasvir)—marketed as Mavyret...

Read More Read more about Ending the "Wait-and-See" Era: AbbVie’s Maviret Redefines Hepatitis C Treatment

Beyond the Treatment Calendar: A Paradigm Shift in Breast Cancer Survivorship

• Psychosocial Support and Mental Health

Beyond the Treatment Calendar: A Paradigm Shift in Breast Cancer Survivorship

Ali Ikhwan August 6, 2026

The American Society of Clinical Oncology (ASCO) Annual Meeting has long been regarded as the global stage...

Read More Read more about Beyond the Treatment Calendar: A Paradigm Shift in Breast Cancer Survivorship

The Vanguard of Innovation: ASPS and MedTech Innovator Select Top Startups for 2026 Accelerator

• Breast Cancer Surgery and Reconstruction

The Vanguard of Innovation: ASPS and MedTech Innovator Select Top Startups for 2026 Accelerator

Raul Delapena Setiawan August 6, 2026

In a move set to redefine the boundaries of reconstructive and aesthetic medicine, the American Society of...

Read More Read more about The Vanguard of Innovation: ASPS and MedTech Innovator Select Top Startups for 2026 Accelerator

Medtronic Expands Electrophysiology Horizon: Sphere-9 System Secures CE Mark for Ventricular Arrhythmia Treatment

• Treatment Innovations

Medtronic Expands Electrophysiology Horizon: Sphere-9 System Secures CE Mark for Ventricular Arrhythmia Treatment

Ali Ikhwan August 6, 2026

In a significant advancement for cardiovascular medicine, Medtronic has announced that its innovative Sphere-9 catheter, integrated with...

Read More Read more about Medtronic Expands Electrophysiology Horizon: Sphere-9 System Secures CE Mark for Ventricular Arrhythmia Treatment

FDA Approves Gedatolisib (Revtorpyk®) for Advanced HR+/HER2- Breast Cancer: A New Paradigm in Overcoming Endocrine Resistance

• Patient Advocacy and Support

FDA Approves Gedatolisib (Revtorpyk®) for Advanced HR+/HER2- Breast Cancer: A New Paradigm in Overcoming Endocrine Resistance

Nana Muazin August 6, 2026

In a landmark decision that promises to reshape the treatment landscape for the most common subtype of...

Read More Read more about FDA Approves Gedatolisib (Revtorpyk®) for Advanced HR+/HER2- Breast Cancer: A New Paradigm in Overcoming Endocrine Resistance

Beyond the "All Clear": Breast Cancer Canada Launches Landmark Initiative to Redefine Survivorship

• Global Breast Cancer Awareness

Beyond the "All Clear": Breast Cancer Canada Launches Landmark Initiative to Redefine Survivorship

Rifan Muazin August 6, 2026

As medical science achieves unprecedented milestones in breast cancer treatment, the definition of success is undergoing a...

Read More Read more about Beyond the "All Clear": Breast Cancer Canada Launches Landmark Initiative to Redefine Survivorship